(Lymphoma) Mundesine Receives New Drug Approval in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
We would like to introduce a new drug for peripheral T-cell lymphoma (PTCL): Mundesine (forodesine). On March 30, Mundipharma K.K. announced that Mundesine can be used as a treatment for relapsed or refractory peripheral T-cell lymphoma. Japan is the first country in the world to obtain drug approval for this indication.
Peripheral T-cell lymphoma is characterized by NK cell involvement and lymphoma cell infiltration into various organs throughout the body. The disease primarily affects individuals aged 65 and older, with incidence increasing with age. Since the early 1990s, various chemotherapy regimens — such as CHOP therapy (cyclophosphamide, doxorubicin/hydroxydaunorubicin, vincristine/Oncovin, and prednisone/prednisolone) — have been used as first-line treatment for moderate to highly malignant non-Hodgkin's lymphoma. However, progress in the treatment of PTCL specifically has been limited, and treatment often causes severe side effects. Treatment generally centers on chemotherapy; historical statistics from 1985–2011 show modest outcomes in terms of both PFS and OS.
The newly approved drug is a PNP (purine nucleoside phosphorylase) inhibitor — the world's first drug of this novel mechanism of action to receive approval. It works by blocking intracellular dGTP (deoxyguanosine triphosphate), inducing apoptosis, and suppressing T-cell-driven tumor proliferation. Additionally, as an oral drug, it reduces the burden of frequent hospital visits, allowing patients to rest and recover at home. For the official press release, please refer to:
Source: http://mundipharma.co.jp/947
Note: The drug name has not been confirmed at the time of writing; the above information is a direct translation based on the company's press release. Please refer to the company's official announcements for the most accurate information.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5